Navigation Links
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)

BARCELONA, Spain, November 5 /PRNewswire/ -- SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers). In an Approvable Letter received on April 6, 2006, the FDA requested additional data with respect to chemistry, manufacturing, and controls (CMC).

SALVAT expects the FDA to classify the complete response as a Class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within 180 days from the time of resubmission. SALVAT believes that the response submitted today to the FDA fully addresses the Agency request.

The Approvable Letter did not raise any questions related to efficacy or safety of CETRAXAL(R) Otic Solution.

SALVAT is currently evaluating potential commercial partners in the United States to licensing out CETRAXAL(R) and expects to launch it during the second quarter of 2009, subject to FDA approval.

The NDA for CETRAXAL(R) seeks marketing approval for the treatment of Acute Otitis Externa in pediatric (aged 1 year and older) and adult patients.


CETRAXAL(R) is a Ciprofloxacin 0.2% Otic Solution for the treatment of Acute Otitis Externa. In a phase III clinical trial compared to Neomycin, Polymyxin B sulfates and Hydrocortisone otic solution (NPH), CETRAXAL(R) obtained a clinical cure rate of 93.9% in pediatric patients (vs. 76.0% in the NPH group) and resolved or improved otalgia in 99.2% of the patients. There were no adverse reactions with an incidence higher than 1%. CETRAXAL(R) will be available in sterile, preservative-free single-dose containers which make easy to ensure correct dosing and to place drops into the ear.


SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced NCE is SVT-40776 for the treatment of Overactive Bladder, which has recently finished phase II. In 2007 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments and by emphasizing collaborations regarding its pipeline products.


Cristina Viayna,

Business Development & Licensing, ,

Phone: +1-305-774-9727.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
2. Telik Announces Financial Results for 2008 Third Quarter
3. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
4. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
5. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
6. Environmental Tectonics Corporation Announces Staff Addition to Its BioMedical Systems Division
7. Misonix Announces New Distribution Agreement for The Netherlands
8. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Post Your Comments:
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together dozens ... BIG ideas to improve health and wellness in their schools. , Now, the top ... of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and an ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
Breaking Biology Technology:
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... Oct. 27, 2015 In the present market ... concern for various industry verticals such as banking, healthcare, ... the growing demand for secure & simplified access control ... such as hacking of bank accounts, misuse of users, ... such as PC,s, laptops, and smartphones are expected to ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):